emtriva.co.uk Report : Visit Site

Technical data of the emtriva.co.uk

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host emtriva.co.uk. Currently, hosted in United Kingdom and its service provider is NetNames Operations Limited .

the related websites

royaltypharma.com aidsmap.com accessdata.fda.gov i-base.info netdoctor.co.uk thepecostrailinn.com surreyandsussex.nhs.uk 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Microsoft-IIS/8.0 containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

'); '); contact | sitemap | about senior management worldwide operations ethics business conduct business partnerships corporate history timeline medicines request information consumer product safety improvement act authorized distributors of record product approval timeline anti-counterfeiting research pipeline clinical trials investigator sponsored research conquering hepatitis via micro-elimination expanded access responsibility year in review 2017 gilead compass initiative™ u.s. patient access developing world access corporate contributions policy perspectives gilead foundation hcv elimination supplier code news press releases company statements events media faqs fact sheets and infographics media inquiries our stories investors recent news corporate governance stock information financial information earnings sec filings shareholder center annual reports e-mail alerts investor faqs investor contacts investor disclaimer careers research pipeline our values developing world access corporate responsibility u.s. benefits inclusion & diversity internships exit player loading the player ... hiv / aids liver diseases hematology / oncology cardiovascular inflammation / respiratory other therapies hiv / aids gilead plays a central role in developing single tablet regimens – with one pill once a day, patients can take all of their medication in each dose. product info pipeline info liver diseases our liver disease programs focus on expanding treatment options for chronic hepatitis b and c. product info pipeline info hematology / oncology our scientists are applying new knowledge about how cancers grow and spread to potentially enhance and improve cancer therapy. product info pipeline info cardiovascular our medicines aim to help patients with cardiovascular disease return to their daily activities, and we are exploring potential new indications. product info pipeline info inflammation / respiratory we research and develop treatments for serious respiratory conditions such as influenza, cystic fibrosis and other diseases of the lungs. product info pipeline info other therapies gilead medicines treat severe fungal and parasitic infections, and address vision loss caused by degenerative eye diseases. product info pipeline info gilead launches hcv micro-elimination program gilead’s medical affairs team is providing research grants to support the who’s goal of eliminating hepatitis c virus (hcv) by 2030. find out more . first quarter 2018 financial results access earnings press release, webcast link and slides for gilead’s first quarter 2018 financial results. view materials. news june 11, 2018 gilead sciences’ chief scientific officer john mchutchison appointed officer of the order of australia about gilead senior management worldwide operations ethics business conduct business partnerships corporate history timeline research pipeline clinical trials investigator sponsored research medicines request information consumer product safety authorized distributors of record product approval timeline responsibility u.s. patient access developing world access corporate contributions policy perspectives gilead foundation news press releases events media faqs fact sheets media inquiries investors recent news corporate governance stock information financial information sec filings shareholder center annual reports email alerts investor faqs investor contacts investor disclaimer careers pipeline our values developing-world-access corporate-contributions u.s. benefits © 2009-2018 gilead. all rights reserved. terms of use | privacy statements | cookie statement product images shown do not represent actual size.

URL analysis for emtriva.co.uk

http://www.gilead.com/about/business-conduct
http://www.gilead.com/responsibility/developing-world-access
http://www.gilead.com/medicines#inflammationrespiratory
http://www.gilead.com/liverdiseases
http://www.gilead.com/research
http://www.gilead.com/research/conquering-hepatitis-via-micro-elimination
http://www.gilead.com/responsibility/supplier-code
http://www.gilead.com/news/media-faqs
http://www.gilead.com/research/pipeline#other
http://www.gilead.com/responsibility/policy-perspectives
http://www.gilead.com/research/pipeline#hematologyoncology
http://www.gilead.com/responsibility/us-patient-access
http://www.gilead.com/research/pipeline#inflammationrespiratory
http://www.gilead.com/medicines#other
http://www.gilead.com/news/our-stories

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Error for "emtriva.co.uk".

the WHOIS query quota for 2600:3c03:0000:0000:f03c:91ff:feae:779d has been exceeded
and will be replenished in 473 seconds

WHOIS lookup made at 07:09:34 07-Sep-2017

--
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:

Copyright Nominet UK 1996 - 2017.

You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at http://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.

  REFERRER http://www.nominet.org.uk

  REGISTRAR Nominet UK

SERVERS

  SERVER co.uk.whois-servers.net

  ARGS emtriva.co.uk

  PORT 43

  TYPE domain

DISCLAIMER
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:
Copyright Nominet UK 1996 - 2017.
You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at http://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.

  REGISTERED no

DOMAIN

  NAME emtriva.co.uk

NSERVER

  NS2.NETNAMES.NET 185.83.102.12

  NS1.NETNAMES.NET 204.74.108.253

  NS6.NETNAMES.NET 204.74.109.253

  NS5.NETNAMES.NET 185.83.100.15

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .